Article Versions Notes

Signoriello E, Lus G, Saccà F, Puthenparampil M, Coppola C, Di Pietro A, Puoti G, Criscuolo MC, Foschi M, Miele G, et al. Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence. Journal of Clinical Medicine. 2023; 12(5):1768. https://doi.org/10.3390/jcm12051768

Signoriello, Elisabetta, Giacomo Lus, Francesco Saccà, Marco Puthenparampil, Cinzia Coppola, Andrea Di Pietro, Gianfranco Puoti, Maria Cristina Criscuolo, Matteo Foschi, Giuseppina Miele, and et al. 2023. "Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence" Journal of Clinical Medicine 12, no. 5: 1768. https://doi.org/10.3390/jcm12051768

Signoriello, E., Lus, G., Saccà, F., Puthenparampil, M., Coppola, C., Di Pietro, A., Puoti, G., Criscuolo, M. C., Foschi, M., Miele, G., Abbadessa, G., Brescia Morra, V., Gallo, P., Bonavita, S., Sormani, M. P., & Signori, A. (2023). Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence. Journal of Clinical Medicine, 12(5), 1768. https://doi.org/10.3390/jcm12051768